ATE428796T1 - Oligosaccharide, herstellungsverfahren und verwendung dafür sowie sie enthaltende pharmazeutische zusammensetzungen - Google Patents
Oligosaccharide, herstellungsverfahren und verwendung dafür sowie sie enthaltende pharmazeutische zusammensetzungenInfo
- Publication number
- ATE428796T1 ATE428796T1 AT05730715T AT05730715T ATE428796T1 AT E428796 T1 ATE428796 T1 AT E428796T1 AT 05730715 T AT05730715 T AT 05730715T AT 05730715 T AT05730715 T AT 05730715T AT E428796 T1 ATE428796 T1 AT E428796T1
- Authority
- AT
- Austria
- Prior art keywords
- oligosaccharides
- pharmaceutical compositions
- production process
- compositions containing
- heparin
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title abstract 3
- 150000002482 oligosaccharides Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003055 low molecular weight heparin Substances 0.000 abstract 2
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 238000013375 chromatographic separation Methods 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0401810A FR2866650B1 (fr) | 2004-02-24 | 2004-02-24 | Oligosaccharides, procede de preparation, utilisation et compositions pharmaceutiques les renfermant |
| PCT/FR2005/000431 WO2005090591A1 (fr) | 2004-02-24 | 2005-02-23 | Oligosaccharides, procede de preparation, utilisation et compositions pharmaceutiques les renfermant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE428796T1 true ATE428796T1 (de) | 2009-05-15 |
Family
ID=34833989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05730715T ATE428796T1 (de) | 2004-02-24 | 2005-02-23 | Oligosaccharide, herstellungsverfahren und verwendung dafür sowie sie enthaltende pharmazeutische zusammensetzungen |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20070142323A1 (de) |
| EP (1) | EP1720994B1 (de) |
| JP (1) | JP2007522823A (de) |
| KR (1) | KR20070006749A (de) |
| CN (1) | CN1938429A (de) |
| AT (1) | ATE428796T1 (de) |
| AU (1) | AU2005224415B2 (de) |
| BR (1) | BRPI0507976A (de) |
| CA (1) | CA2554555A1 (de) |
| DE (1) | DE602005013925D1 (de) |
| ES (1) | ES2325549T3 (de) |
| FR (1) | FR2866650B1 (de) |
| IL (1) | IL177535A (de) |
| WO (1) | WO2005090591A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070099867A1 (en) * | 2005-05-24 | 2007-05-03 | Glycoscience Laboratories, Inc. | Pharmaceutical agent containing hyaluronan as an active ingredient |
| JP2009091248A (ja) * | 2006-01-17 | 2009-04-30 | Toshitsu Kagaku Kenkyusho:Kk | 外傷性神経障害および／または運動機能障害の治療薬 |
| EP1994934A4 (de) | 2006-12-05 | 2010-03-10 | Glycoscience Lab Inc | Therapeutisches mittel gegen degenerative arthritis |
| EP2205642B1 (de) * | 2007-11-02 | 2016-01-27 | Momenta Pharmaceuticals, Inc. | Nicht gerinnungshemmende polysaccharidzusammensetzungen |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8569262B2 (en) * | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| BR112012026542A2 (pt) | 2010-04-16 | 2016-07-12 | Momenta Pharmaceuticals Inc | abordagem seletiva de tecido |
| AU2011268470B2 (en) | 2010-06-17 | 2017-02-02 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
| CN102323355B (zh) * | 2011-08-22 | 2013-10-16 | 深圳市天道医药有限公司 | 一种酶解-hplc法检测依诺肝素的方法 |
| US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| CN105037452B (zh) * | 2015-06-19 | 2018-10-09 | 天津红日药业股份有限公司 | 一种快速制备高纯度磺达肝癸钠的精制方法 |
| EP3146971A1 (de) * | 2015-09-28 | 2017-03-29 | Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) | Antimetastatisches derivat aus marinen bakteriellen exopolysacchariden und verwendungen davon |
| CN105504097B (zh) * | 2015-12-30 | 2018-07-03 | 深圳市海普瑞药业集团股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
| EP3398971A4 (de) * | 2015-12-30 | 2019-09-25 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Sulfatiertes heparinoligosaccharid und herstellungsverfahren und anwendung davon |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
| US4396762A (en) * | 1981-08-24 | 1983-08-02 | Massachusetts Institute Of Technology | Heparinase derived anticoagulants |
| US4916219A (en) * | 1985-03-28 | 1990-04-10 | University Of Iowa Research Foundation | Oligosaccharide heparin fragments as inhibitors of complement cascade |
| US4847338A (en) * | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
| US5106734A (en) * | 1986-04-30 | 1992-04-21 | Novo Nordisk A/S | Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin |
| PT93847A (pt) * | 1989-04-24 | 1990-11-20 | Harvard College | Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| US5296471A (en) * | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
| JP3500788B2 (ja) * | 1995-07-31 | 2004-02-23 | Ｎｏｋ株式会社 | フレキシブルブーツ |
| US6969705B2 (en) * | 2000-07-21 | 2005-11-29 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| US20040171819A1 (en) * | 2002-10-10 | 2004-09-02 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
-
2004
- 2004-02-24 FR FR0401810A patent/FR2866650B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-23 WO PCT/FR2005/000431 patent/WO2005090591A1/fr not_active Ceased
- 2005-02-23 BR BRPI0507976-4A patent/BRPI0507976A/pt not_active IP Right Cessation
- 2005-02-23 AT AT05730715T patent/ATE428796T1/de not_active IP Right Cessation
- 2005-02-23 CN CNA2005800056769A patent/CN1938429A/zh active Pending
- 2005-02-23 EP EP05730715A patent/EP1720994B1/de not_active Expired - Lifetime
- 2005-02-23 CA CA002554555A patent/CA2554555A1/fr not_active Abandoned
- 2005-02-23 DE DE602005013925T patent/DE602005013925D1/de not_active Expired - Lifetime
- 2005-02-23 ES ES05730715T patent/ES2325549T3/es not_active Expired - Lifetime
- 2005-02-23 AU AU2005224415A patent/AU2005224415B2/en not_active Withdrawn - After Issue
- 2005-02-23 KR KR1020067016885A patent/KR20070006749A/ko not_active Abandoned
- 2005-02-23 JP JP2007500254A patent/JP2007522823A/ja not_active Ceased
-
2006
- 2006-08-16 IL IL177535A patent/IL177535A/en not_active IP Right Cessation
- 2006-08-23 US US11/508,800 patent/US20070142323A1/en not_active Abandoned
-
2010
- 2010-01-21 US US12/691,337 patent/US20100249061A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100249061A1 (en) | 2010-09-30 |
| BRPI0507976A (pt) | 2007-07-24 |
| KR20070006749A (ko) | 2007-01-11 |
| CA2554555A1 (fr) | 2005-09-29 |
| ES2325549T3 (es) | 2009-09-08 |
| EP1720994B1 (de) | 2009-04-15 |
| US20070142323A1 (en) | 2007-06-21 |
| WO2005090591A1 (fr) | 2005-09-29 |
| IL177535A0 (en) | 2006-12-10 |
| AU2005224415A1 (en) | 2005-09-29 |
| FR2866650A1 (fr) | 2005-08-26 |
| JP2007522823A (ja) | 2007-08-16 |
| IL177535A (en) | 2010-12-30 |
| EP1720994A1 (de) | 2006-11-15 |
| FR2866650B1 (fr) | 2006-04-28 |
| CN1938429A (zh) | 2007-03-28 |
| AU2005224415B2 (en) | 2011-06-02 |
| DE602005013925D1 (de) | 2009-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005013925D1 (de) | Oligosaccharide, herstellungsverfahren und verwendung dafür sowie sie enthaltende pharmazeutische zusammensetzungen | |
| Mycroft-West et al. | Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin | |
| Taylor | Supercritical fluid chromatography | |
| Ugbe et al. | Computational evaluation of the inhibitory potential of some urea, thiourea, and selenourea derivatives of diselenides against leishmaniasis: 2D-QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation | |
| Krokidas et al. | ZIF-67 framework: a promising new candidate for propylene/propane separation. experimental data and molecular simulations | |
| Lee et al. | Scientific considerations in the review and approval of generic enoxaparin in the United States | |
| Varenne et al. | Capillary electrophoresis determination of the binding affinity of bioactive sulfated polysaccharides to proteins: study of the binding properties of fucoidan to antithrombin | |
| Schiel et al. | Measurement of drug-protein dissociation rates by high-performance affinity chromatography and peak profiling | |
| Cavallero et al. | Resolving heparan sulfate oligosaccharide positional isomers using hydrophilic interaction liquid chromatography-cyclic ion mobility mass spectrometry | |
| BRPI0810322A2 (pt) | "CÉLULA EBx DE AVE TRANSFECTADA, MÉTODO DE PRODUÇÃO DE PELO MENOS UM PRODUTO BIOLÓGICO DE INTERESSE, PRODUTO BIOLÓGICO DE INTERESSE, POPULAÇÃO DE ANTICORPO, ANTICORPOS, USOS DE UM PRODUTO BIOLÓGICO E DE UM ANTICORPO OU UM FRAGMENTO DESTE E COMPOSIÇÃO FARMACÊUTICA" | |
| Fukazawa et al. | Reduction of non-specific adsorption of drugs to plastic containers used in bioassays or analyses | |
| Laguri et al. | 13C-labeled heparan sulfate analogue as a tool to study protein/heparan sulfate interactions by NMR spectroscopy: application to the CXCL12α chemokine | |
| DK1720544T3 (da) | Nye azabicykliske derivater, fremstillingsmetode hertil og farmaceutiske sammensætninger indeholdende disse | |
| Zhu et al. | Frontal affinity chromatography combined on-line with mass spectrometry: a tool for the binding study of different epidermal growth factor receptor inhibitors | |
| Guo et al. | Development of a HPLC method for the quantitative determination of capsaicin in collagen sponge | |
| Baydemir et al. | Heparin removal from human plasma using molecular imprinted cryogels | |
| Rops et al. | Heparan sulfate on activated glomerular endothelial cells and exogenous heparinoids influence the rolling and adhesion of leucocytes | |
| Dinges et al. | Affinity capillary electrophoresis for the determination of binding affinities for low molecular weight heparins and antithrombin‐III | |
| NEWLY | Lipophilicity assessment of spironolactone by means of reversed phase liquid chromatography and by newly developed calculation procedures | |
| Gesslbauer et al. | New targets for glycosaminoglycans and glycosaminoglycans as novel targets | |
| Zhao et al. | Honeycomb resin-based spin-column solid-phase extraction for efficient determination of alectinib and its metabolite in human urine | |
| Šegan et al. | Investigation of lipophilicity and pharmacokinetic properties of 2-(methoxy) phenylpiperazine dopamine D2 ligands | |
| Mernie et al. | Untangling Heparan Sulfate 3‑O‑Sulfation Using a Novel Offline Cationic-Peptide Affinity Enrichment, Followed by HILIC-cIM-MS | |
| CN106706746B (zh) | 毛细管电泳结合uplc-ms分析pqq对儿茶酚胺神经递质调节作用的研究方法 | |
| Babazada et al. | Binding and structure-kinetic relationship analysis of selective TLR4-targeted immunosuppressive self-assembling heparin nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |